Residual cancer can remain undetected despite clear scans, potentially leading to worse outcomes and higher risks of ...

"Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma." ...

Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD.

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) climbed in the morning hours on Friday after Goldman Sachs upgraded the stock to Buy from Neutral, arguing that the cancer test maker operates in an ...

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

The third among the 10 stocks insiders are getting rid of in March is a commercial-stage biotech, Adaptive Biotechnologies ...

Cancer research breakthroughs will have profound impacts on the life insurance industry. What advisors need to know.

Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to ...

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.